Seattle Genetics Down over 3.5%, May be Attributed to Analyst Call on Adverse Affects on Drug

by Allie Wickman, Benzinga Staff Writer
December 1, 2011 11:13 AM | 1 seconds read | Make a Comment
Loading...
Loading...
View tweet
here
.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In: NewsFDAIntraday UpdateMoversMedia
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!